Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

American Journal of Cardiology

Volumn 94, Issue 6, 2004, Pages 789-792

  Cheneau, Edouard ^a   Canos, Daniel ^a   Kuchulakanti, Pramod K ^a   Rha, Seung Woon ^a   Satler, Lowell F ^a   Suddath, William O ^a   Kent, Kenneth M ^a   Pichard, Augusto D ^a   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIRULOG;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPRODUCIBILITY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERIOSCLEROSIS; FEMALE; HIRUDINS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; WHOLE BLOOD COAGULATION TIME;

EID: 4544241581     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.05.068     Document Type: Article

References (10)

1. A.R. Gruntzig, A. Senning, W.E. Siegenthaler Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty N Engl J Med 301 1979 61 68
2. M. Ragosta, M. Karve, D. Brezynski, M. Ragosta, M. Karve, D. Brezynski, J. Humphries, J.M. Sanders, I.J. Sarembock, L.W Gimple Effectiveness of heparin in preventing thrombin generation and thrombin activity in patients undergoing coronary intervention Am Heart J 137 1999 250 257
3. B. Rath, D.H. Bennett Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty Br Heart J 63 1990 18 21
4. J.J. Ferguson, K.G. Dougherty, C.M. Gaos, H.S. Bush, K.C. Marsh, D.R. Leachman Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty J Am Coll Cardiol 23 1994 1061 1065
5. A.M. Lincoff, J.A. Bittl, R.A. Harrington, F. Feit, N.S. Kleiman, J.D. Jackman, I.J. Sarembock, D.J. Cohen, D. Spriggs, R Ebrahimi REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
6. J.A. Bittl, J. Strony, J.A. Brinker, W.H. Ahmed, C.R. Meckel, B.R. Chaitman, J. Maraganore, E. Deutsch, B. Adelman Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina Hirulog Angioplasty Study Investigators N Engl J Med 333 1995 764 769
7. C.R. Narins, W.B. Hillegass Jr, C.L. Nelson, J.E. Tcheng, R.A. Harrington, H.R. Phillips, R.S. Stack, R.M. Califf Relation between activated clotting time during angioplasty and abrupt closure Circulation 93 1996 667 671
8. W.B. Hillegass, B.C. Brott, G.D. Chapman, H.R. Phillips, R.S. Stack, J.E. Tcheng, R.M. Califf Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications Am Heart J 144 2002 501 507
9. D.P. Chew, D.L. Bhatt, A.M. Lincoff, D.J. Moliterno, S.J. Brener, K.E. Wolski, E.J. Topol Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials Circulation 103 2001 961 966
10. T.R. Tolleson, J.C. O'Shea, J.A. Bittl, W.B. Hillegass, K.A. Williams, G. Levine, R.A. Harrington, J.E. Tcheng Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial J Am Coll Cardiol 41 2003 386 393